Kilitch Drugs (India) Limited

NSEI:KILITCH 주식 보고서

시가총액: ₹5.0b

Kilitch Drugs (India) 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mukund Mehta

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기32.5yrs
CEO 소유권7.1%
경영진 평균 재임 기간2.5yrs
이사회 평균 재임 기간7.2yrs

최근 관리 업데이트

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Sep 23
Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Recent updates

Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Jul 23
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Mar 05
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

Feb 02
Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Jan 30
We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Nov 17
Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Sep 23
Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Sep 08
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

May 05
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Jul 06
Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

Apr 08
Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Mar 21
Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 13
Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Dec 03
Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Aug 20
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jul 16
Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

CEO 보상 분석

Mukund Mehta 의 보수는 Kilitch Drugs (India) 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

₹165m

Jun 30 2024n/an/a

₹126m

Mar 31 2024n/an/a

₹146m

Dec 31 2023n/an/a

₹146m

Sep 30 2023n/an/a

₹140m

Jun 30 2023n/an/a

₹117m

Mar 31 2023₹6m₹6m

₹104m

Dec 31 2022n/an/a

₹98m

Sep 30 2022n/an/a

₹85m

Jun 30 2022n/an/a

₹83m

Mar 31 2022₹6m₹6m

₹74m

Dec 31 2021n/an/a

₹52m

Sep 30 2021n/an/a

₹63m

Jun 30 2021n/an/a

₹62m

Mar 31 2021₹6mn/a

₹37m

Dec 31 2020n/an/a

₹17m

Sep 30 2020n/an/a

₹4m

Jun 30 2020n/an/a

-₹3m

Mar 31 2020₹6mn/a

₹8m

보상 대 시장: Indian 시장에서 비슷한 규모의 회사에 비해 Mukund 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Mukund 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Mukund Mehta (71 yo)

32.5yrs

테뉴어

₹6,000,000

보상

Mr. Mukund Prataprai Mehta, B.Com, LL B., serves as the Chairman and Managing Director at Kilitch Drugs (India) Limited and has been its Executive Director since May 12, 1992. Mr. Mehta served as the Compl...

리더십 팀

이름위치테뉴어보상소유권
Mukund Mehta
Executive Chairman & MDno data₹6.00m7.09%
₹ 352.5m
Mira Mehta
Managing Directorless than a year₹2.40m5.23%
₹ 259.9m
Bhavin Mehta
Whole-time Directorno data₹8.40m15.69%
₹ 779.8m
Sunil Jain
Chief Financial Officer3.7yrs₹1.50m데이터 없음
Tajouddin Ansari
VP-Marketing & Operationno data데이터 없음데이터 없음
Rajesh Khatri
General Manager - Administrationno data데이터 없음데이터 없음
Pushpa Nyoupane
Company Secretary & Compliance Officer2.5yrs데이터 없음데이터 없음

2.5yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: KILITCH 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Mukund Mehta
Executive Chairman & MD32.5yrs₹6.00m7.09%
₹ 352.5m
Mira Mehta
Managing Director10yrs₹2.40m5.23%
₹ 259.9m
Bhavin Mehta
Whole-time Director7.2yrs₹8.40m15.69%
₹ 779.8m
Hemang Engineer
Independent & Non Executive Director16.4yrs₹25.00k데이터 없음
Vasudev Murti
Non-Executive Independent Director6.7yrs₹30.00k데이터 없음
Venkita Rajan
Independent Non-Executive Director6.4yrs₹5.00k데이터 없음
Dipen Jain
Non- Executive Independent Directorless than a year데이터 없음데이터 없음

7.2yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: KILITCH 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.